Testing the recovery and lifespan of treated red blood cells
This study tests a new way to treat donated red blood cells (called INTERCEPT) to see how long they survive in the body and how well they recover. It may help make blood transfusions safer for people who need them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your blood counts and chemistry tests must be within normal limits, or if slightly off, your doctor must consider them not a problem.
- You cannot have a history of red blood cell disorders (like sickle cell disease, thalassemia, or G6PD deficiency) or autoimmune diseases that affect red blood cells.
- You cannot have taken medications that weaken the immune system (like prednisone) in the past 28 days.
- If you are able to have children, you must agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a special way to label your own red blood cells so doctors can track how long they survive in your body. It helps improve how we measure blood cell recovery after transfusion.
This study checks if a special treatment to reduce germs in red blood cells is safe for patients who may have developed antibodies from past transfusions. You will receive a small transfusion of these treated cells to see how your body reacts.
This study collects and stores blood/blood-cell samples so researchers can use them for approved future studies. You would be tested for certain infections and health measurements to make sure the collection procedure is safe for you.
This trial tests whether using a measure of oxygen in your body can guide doctors on when to give you a blood transfusion. It may help avoid unnecessary transfusions while ensuring you get enough oxygen.
This study tests a special system (Hemanext One) that stores red blood cells with less oxygen, to see if it helps people with thalassemia who need regular transfusions. It may reduce side effects or improve how well the transfusions work.
This study compares two different strategies for when to give red blood cell transfusions to people receiving intensive chemotherapy or stem cell transplant for high-grade myeloid neoplasms, AML or B-ALL. The goal is to see which approach better improves quality of life and daily function.
Hear when a new Healthy Subjects trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.